BOCA RATON, Fla. , Sept. 28, 2023 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the shipment of an SRT-100+™ System to Cape Cod Hospital in Hyannis, Massachusetts, the second SRT-100+ System sold to a hospital in Massachusetts. This sale represents the Company’s ongoing success in the U.S. Northeast region as treating skin cancer with Sensus SRT technology continues to draw interest from community hospital oncology departments.
Jeffrey Martin, M.D., a radiation oncologist at Cape Cod Hospital, said, “Non-melanoma skin cancers affect many patients we serve. For those who may not be candidates for surgery, or prefer a non-invasive alternative, radiation therapy is an effective treatment option. This is particularly relevant for our population on the Cape as many elderly residents who lived active lives with significant sun exposure are at increased risk for skin cancer. Superficial radiotherapy offers an advantage with its ease of setup and positioning, while allowing for the treatment of smaller fields than other forms of radiotherapy.”
Commenting on the sale, Joe Sardano, chairman and chief executive officer of Sensus Healthcare, said, “More and more hospitals around the country are inquiring about SRT as they consider making non- invasive skin cancer treatments available in their communities. It is becoming increasingly commonplace for hospitals to treat a larger population suffering with cancer on an outpatient basis, and our SRT systems offer an ideal non-surgical, painless and cosmetically appealing option while also helping hospitals to improve resource utilization.”
Sensus will be demonstrating its superficial radiotherapy products at the American Society for Radiation Oncology (ASTRO) Annual Meeting October 1-4 in San Diego. ASTRO 2023 participants are invited to visit Sensus Healthcare at Booth 2553 in the San Diego Convention Center to witness live product demonstrations and interact with the company’s knowledgeable representatives. To schedule an appointment or for more information about Sensus Healthcare’s participation, please contact Sensus Healthcare by visiting www.sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ‘forward-looking statements.’ In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2023; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
To date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have not had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
